Information Provided By:
Fly News Breaks for February 28, 2020
NEO
Feb 28, 2020 | 05:31 EDT
First Analysis analyst Joseph Munda upgraded NeoGenomics to Strong Buy from Outperform with an unchanged price target of $35. The issues expected in Q1 are transitory and Q2 should bring a rebound in both revenue growth and earnings, Munda tells investors in a research note. As such, he sees the 8% selloff post earnings as a "compelling opportunity to start a position or increase holdings."
News For NEO From the Last 2 Days
There are no results for your query NEO